Effect of Psychedelic VR-augmented Therapy on Patients With Clinical Depression
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Therapeutic Intervention with Psychedelic Virtual Reality, Therapeutic Intervention with Non-Psychedelic Virtual Reality.
- Who it may be relevant to
- Registry conditions: Depression. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Estonia
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Research has demonstrated that psychedelic compounds possess significant therapeutic potential for a variety of disorders, including depression. Despite these findings, the underlying mechanisms driving the therapeutic efficacy of psychedelics remain elusive. Furthermore, there exists a debate over the contribution of the subjective psychedelic experience to their therapeutic benefits. In this study, virtual reality (VR) is utilized as a tool to replicate the subjective experiences induced by psychedelics, aiming to explore their impact on depressive symptoms within a clinical sample. The primary objective of this research is to examine the influence of psychedelic-like phenomenology, as simulated through VR, on depressive symptoms. The study is structured into two distinct arms: the experimental condition features 'Psyrreal,' a VR experience designed to emulate psychedelic effects and the control condition which includes 'Routine Realms,' an analogous VR experience devoid of psychedelic elements. A third waiting list condition may be included, dependent on the availability of sufficient participants and resources. Additionally, the study seeks to identify and analyze various potential mediators that might underpin the therapeutic outcomes observed.
Interventions
- Other Therapeutic Intervention with Psychedelic Virtual Reality
A 55-minute immersive psychedelic virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience. - Other Therapeutic Intervention with Non-Psychedelic Virtual Reality
A 55-minute immersive virtual reality experience is incorporated into a therapeutic intervention, comprising a preparatory phase and a subsequent integration session based on the individual's experience.
Primary outcome measures
- Change in Emotional State Questionnaire 2 depression subscale score from baseline to follow-up [Time frame: Measured at 3 time-points - on the day 1 of intervention, and two weeks and two months after intervention.]
Secondary outcome measures (8)
- Short mood questionnaire [Time frame: Measured at two time-points - baseline and on the day 1 of the intervention..]
- Emotional State Questionnaire 2 other subscales [Time frame: Measured at 3 time-points - on the day 1 of intervention and two weeks and two months after intervention.]
- State Mindfulness Scale [Time frame: Measured at two time-points -baseline and on the day 1 of the intervention]
- Adapted short version of the questionnaire for the assessment of altered states of consciousness (11D-ASC) [Time frame: Measured at one time-point - after the virtual reality experience on the day 1 of the intervention.]
- Psychological Insight Questionnaire [Time frame: Measured at one time-point - after the virtual reality experience on the day 1 of the intervention.]
- Ego-Dissolution Inventory [Time frame: Measured at one time-point - after the virtual reality experience on the day 1 of the intervention.]
- Avoidance/Acceptance-Promoting Experience Questionnaire [Time frame: Measured at one time-point - after the virtual reality experience on the day 1 of the intervention.]
- Awe Experience Scale [Time frame: Measured at one time-point - after the virtual reality experience on the day 1 of the intervention.]
Eligibility criteria
Inclusion criteria
- Persistent depressive symptoms observed during the initial screening and confirmed at baseline, as determined through a comprehensive psychiatric evaluation.
- Provision of written informed consent by the participant.
- Fluent in Estonian as a native language.
Exclusion criteria
- Presence of significant impairments in vision, hearing, or balance.
- Active suicidal ideation or current engagement in self-harm behaviors. Note: Individuals meeting this criterion will be directed to suitable crisis intervention services.
- Established diagnosis of bipolar disorder.
- Manifestation of psychotic symptoms.
- History of schizophrenia, either personally or within two generations of the family lineage.
- Ongoing diagnosis of epilepsy, dementia, or any other neurological condition that could interfere with the effective utilization of virtual reality (VR) technology.
- Susceptibility to motion sickness.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Estonia · 1 center
- Confido Medical Centre — Tallinn
Identifiers
NCT: NCT06174285 · DB-RCT-PSYRREAL